IP Verse

Vilanterol Formulations - EP2957552

EP2957552

ARVEN ILAC SANAYI VE TICARET
Application Number
EP15172131A
Filing Date
Jun 15, 2015
Status
Revoked
Jun 24, 2022
Grant Date
Jan 22, 2020
External Links
Slate, Register, Google Patents

Bibliography

The patent EP2957552B1 was granted to Arven Ilac Sanayi VE Ticaret on Jan 22, 2020 following the initial filing on Jun 15, 2015 under the application number EP15172131A . The current legal status of the patent is Revoked.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBOct 20, 2020ADMISSIBLE
GILL JENNINGS & EVERYOct 13, 2020ADMISSIBLE
BECK GREENEROct 1, 2020ADMISSIBLE

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONGB2242134
DESCRIPTIONWO03024439
OPPOSITIONWO0178693
OPPOSITIONWO0243701
OPPOSITIONWO2010097115
OPPOSITIONWO2011067212
OPPOSITIONWO2014155134
SEARCHWO2010097115

Non-Patent Literature (NPL) Citations (12) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "5. Particulate Interactions in Dry Powder Aerosols", Xian Ming Zeng et al, Particulate Interactions in Dry Powder Formulations for Inhalation, Taylor & Francis, (20010000), pages 133 - 173, XP055274532-
OPPOSITION- "5. Particulate Interactions in Dry Powder Aerosols", XIAN MING ZENG ET AL, Particulate Interactions in Dry Powder Formulations for Inhalation, TAYLOR & FRANCIS, (2001), pages 133 - 173, XP055274532-
OPPOSITION- Anonymous, "particle size analysis-laser diffraction methods", ISo 13320-1, (19990101), pages 1 - 41, ISo 13320-1, (20181003), XP055512022-
OPPOSITION- FDA, "BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder) FOR ORAL INHALATION USE", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20130000), pages 1 - 41, XP055736888-
OPPOSITION- GlaxoSmithKline, "BREO® ELLIPTA™ now available in the U.S. for the treatment of COPD", P R Newswire, (20131030), URL: https://www.prnewswire.com/news-releases/breo-ellipta-now-available-in-the-us-for-the-treatment-of-copd-229862421.html, XP055745965-
OPPOSITION- "Lactose Inhalation", Rowe Raymond C. et al, The Handbook of Pharmaceutical Excipients. 6th ed., Pharmaceutical Press, (2009), pages 362 - 364, XP055738804-
OPPOSITION- Malvern Instruments Limited, "Basic Principles-Particle-Size-Analysis", Malvern - Application Note, (20140000), URL: https://www.atascientific.com.au/wp-content/uploads/2017/02/AN020710-Basic-Principles-Particle-Size-Analysis.pdf, XP055726651-
OPPOSITION- "Particle size analysis by laser diffraction", EDQM, European Pharmacopoeia. 8th ed., (20130715), page 333, XP055738848-
OPPOSITION- R. MUELLER-WALZ et al., "TERNARY ADDITIVES: MANIPULATION AND CONTROL WITH MAGNESIUM STEARATE", Respiratory Drug Delivery, (20060000), vol. 1, pages 343 - 350, XP055514615-
OPPOSITION- R. GUCHARDI et al., "Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations", International Journal of Pharmaceutics, (20080000), vol. 348, doi:10.1016/j.ijpharm.2007.06.041, pages 10 - 17, XP022393884
OPPOSITION- C.A. DUNBAR et al., "Dispersion and Characterization of Pharmaceutical Dry Powder Aerosols", KONA, (19980000), vol. 16, pages 7 - 45, XP055460404
OPPOSITION- C.A. DUNBAR et al., "Dispersion and Characterization of Pharmaceutical Dry Powder Aerosols", KONA Powder and Particle Journal, (19980101), vol. 16, pages 7 - 45, XP055460404

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents